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Background: Zoledronic acid (ZOL) is an important component of therapy for patients with metastatic
bone disease (MBD) to reduce the risk of skeletal-related events (SREs). We evaluated overall survival
(OS) in patients with MBD secondary to solid tumours included in placebocontrolled ZOL trials.
Patients and methods: Exploratory analyses were performed using databases from three randomised
trials of ZOL versus placebo. 1126 patients (ZOL, n¼731; placebo, n¼395) with complete baseline data
for 18 predeﬁned parameters were evaluated for OS. Relative risks (RRs) with 95% conﬁdence intervals
were assessed using stratiﬁed and adjusted Cox regression models. Baseline covariates deﬁning patient
populations with signiﬁcantly different effects of ZOL treatment on OS (identiﬁed by stepwise
backward elimination) were included in multivariate models.
Results: Although OS was similar between the overall treatment groups, ZOL signiﬁcantly improved OS
in the subset of patients (n¼423; 38%) with elevated baseline NTX (Z100 nmol/mmol creatinine; RR,
0.692; P¼ .0028). Notably, this effect was independent of SRE prevention. Additional covariates
associated with OS beneﬁts with ZOL (e.g., low albumin, SRE history, elevated lactate dehydrogenase,
shorter cancer duration) were characteristic of advanced disease.
Conclusion: These exploratory analyses suggest a beneﬁcial effect of ZOL on OS in patients with highly
aggressive or advanced MBD.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In recent years, intravenous zoledronic acid (ZOL) has become
an integral component of therapy for patients with metastatic
bone disease (MBD) to reduce the risk of skeletal-related events
(SREs) [1]. Initially, ZOL demonstrated superiority over. This is an open access article un
ancer Clinical Trials Centre,
pital, University of Shefﬁeld,
ngdom
Coleman).pamidronate (the former standard of care) for managing hyper-
calcaemia of malignancy (HCM) [2]. Subsequently, across a range
of cancers including breast cancer (BC) [3], castration-refractory
prostate cancer (CRPC) [4], non-small cell lung cancer (NSCLC),
and a variety of other solid tumours (OST) metastatic to bone [5],
placebo-controlled trials have shown that monthly (every 3 to
4 weeks) ZOL reduces the overall risk of SREs by 27% to 41% and
extends the time to ﬁrst and subsequent SREs.
Preclinical and emerging clinical data from multiple settings
also suggest that ZOL has anticancer properties that may delay
disease recurrence and improve survival [6–13]. Recently, ZOL
was shown to improve overall survival (OS) and progression-freeder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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multiple myeloma [10]. Furthermore, in a large, randomised trial
of 1803 premenopausal patients with early endocrine-responsive
BC, ZOL also reduced the risk of disease relapse by 32% versus
endocrine therapy alone (P¼ .009) [8]. Together with interim
results from the AZURE trial in stage II/III BC [14], these data
suggest that anticancer beneﬁts from ZOL may occur in speciﬁc
patient populations, all of which are expected to have elevated
osteolysis levels because of oestrogen deprivation (e.g., premeno-
pausal patients with low-risk BC receiving goserelin, postmeno-
pausal patients receiving letrozole, and patients with stage II/III
BC with established postmenopausal status) [7,8,14].
Despite preventing 430% of SREs, some of which correlate
indirectly or directly with reduced survival [15], ZOL did not
signiﬁcantly increase OS in three placebo-controlled phase III
trials [3–5]. This may be partially attributable to the individual
trials not being powered to detect OS beneﬁt. Additionally, in
many patients death may be related more to overall disease
burden or complications from visceral metastases, aspects of the
disease that a bone-targeted treatment are unlikely to inﬂuence.
It is now evident that overall prognosis is especially poor for
patients with aggressive bone lesions (as evidenced by substan-
tially elevated levels of the bone turnover marker N-telopeptide
of type I collagen [NTX]) [16,17], greater extent of skeletal disease
at baseline [18], or overall high burden of disease (e.g., reﬂected
by hypoalbuminaemia, poor performance status [PS], or rapid
weight loss) [19–23]. Additionally, rapid normalisation of ele-
vated NTX levels during ZOL therapy has been associated with
improved survival versus persistently elevated NTX levels [24,25].
These observations prompted us to perform exploratory analyses
of the potential correlations between baseline disease character-
istics, with particular focus on the rate of bone resorption and
possible survival beneﬁts with ZOL in patients with MBD from
solid tumours who were included in three contemporaneous,
phase III, placebo-controlled trials of ZOL.2. Methods
2.1. Patients and treatment
Three randomised, multicentre, double-blind, placebo-con-
trolled, phase III clinical trials evaluated the safety and efﬁcacy
of ZOL in patients with MBD from a broad range of cancers: BC,
CRPC, or NSCLC and OST [3–5]. These studies were selected for
inclusion because they were contemporaneous trials with sub-
stantial similarity in study designs, endpoints, treatments, sche-
dules for assessments, and types of data collected (including bone
marker estimations). In all three studies, patients had radio-
graphically conﬁrmed MBD, Eastern Cooperative Oncology Group
(ECOG) PSr2, serum creatinine (Cr)r3 mg/dL (265 mmol/L), and
provided written informed consent. Additionally the CRPC study
required disease progression despite serum testosterone o50 ng/
dL, but without bone pain requiring strong opioid therapy [4]. All
patients received standard therapies (cancer-speciﬁc and suppor-
tive care), calcium, and vitamin D throughout the course of the
studies.
The BC study randomised patients to placebo or 4 mg ZOL
monthly, whereas the other two studies randomised patients to
placebo, 4 mg ZOL monthly, or 8 mg ZOL monthly [3–5]. Following
recommendations from a renal safety monitoring committee, the
8-mg ZOL dose was reduced to 4 mg (subsequently referred to as
the 8/4-mg arm) [4,5]. Study treatments were administered for up
to 24 months (CRPC), 21 months (OST), or 12 months (BC) [3–5].
Treatment outcomes were similar between the 4- and 8/4-mg ZOL
groups, and results were pooled as in earlier analyses.2.2. Patient evaluation
All trials evaluated SRE incidence (pathologic fracture, surgery
to bone to treat or prevent an impending fracture, palliative
radiotherapy to bone, spinal cord compression, and HCM; for
patients with CRPC, SREs also included change in antineoplastic
therapy primarily to alleviate bone pain) and collected mortality
data.
Biochemical markers of bone metabolism (serum bone-speciﬁc
alkaline phosphatase [BALP] and NTX) were assessed at baseline
and at deﬁned timepoints during the ﬁrst 12 months on study in
ﬁve central reference laboratories in the United States, Belgium,
Argentina, Brazil, and Japan. Urinary NTX (measured in a morning
second-void sample) was standardised to the level of urinary Cr
and expressed as nmol/mmol Cr. Serum BALP was measured in
International Units (IU)/L in the CRPC and OST studies and in
Units (U)/L in the Japanese BC study. For Japanese patients, the
reference upper limit of normal (ULN) for BALP provided by the
laboratories was 40 U/L, whereas other sites reported a ULN of
146 IU/L.
Patients were assessed for cancer-speciﬁc and overall health
parameters at baseline, including extent of MBD, ECOG PS,
haematologic and nutritional parameters, and bone marker levels.
The current exploratory analyses are limited to patients with
complete data for all baseline assessments (18 predeﬁned para-
meters), including bone markers.
2.3. Statistical methods
The primary outcome of these exploratory analyses was OS
(deﬁned as the interval from study entry to death). In patients
who survived beyond the end of their follow-up (up to 24 months
(CRPC), 21 months (OST), or 12 months (BC) [3–5]), survival time
was censored at the time of study completion. For patients who
prematurely withdrew from the trials, survival time was censored
at the time of withdrawal from the trial.
Earlier studies identiﬁed NTX as prognostic in the bone
metastasis setting [16,17]; therefore, models were developed
with baseline urinary NTX categorised based on the ULN in
postmenopausal women (64 nmol/mmol Cr) or a cutoff value
previously associated with pathologic bone turnover (100 nmol/
mmol Cr) [17]. Parameters such as age, weight, pain, and
haemoglobin level were dichotomised using the median for each
study as the cutpoint.
Biochemical parameters were dichotomised using their
respective established ULNs. Because limits for albumin and
lymphocyte count established in healthy people might not be
relevant for heavily pretreated patients with advanced cancers,
we used different methods to analyse these variables. Baseline
lymphocytes (measured as percentage of total white blood cells)
were dichotomised around the median or characterised using
common quartiles across the three trials. Serum albumin and
creatinine were characterised using quartiles (either study-
speciﬁc or common, depending on the analytic model).
2.4. Assessment of potential treatment modiﬁers
Relative risks (RRs) and 95% conﬁdence intervals (CIs) for
death in ZOL- versus placebo-treated patients were obtained via
Cox regression models [26–28], stratiﬁed by cancer type, and
adjusted for ongoing chemotherapy and baseline calcium levels.
Homogeneity tests were performed to validate the assumption
that treatment effects were common across study populations.
Tests were also conducted to assess treatment-by-covariate
interactions, which would indicate a signiﬁcantly different mag-
nitude of treatment beneﬁt for the different subgroups of patients
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ﬁers assessed included age, weight, cancer duration, brief pain
inventory composite pain score, analgesic use, ECOG PS, prior SRE
(yes/no), lactate dehydrogenase (LDH), haemoglobin, lymphocyte
count, serum glutamic oxaloacetic transaminase, albumin, Cr, and
bone markers. These variables were selected based on assessment
of the trial databases and group discussions involving all aca-
demic authors; the selection was designed to include the largest
possible number of cancer-related and bone-speciﬁc variables to
achieve robust analyses from the available databases. Baseline
covariates associated with a signiﬁcantly different probability of
OS beneﬁt from ZOL treatment (interactive P value for treatment-
by-covariate interaction [Pint]o .05) were identiﬁed using step-
wise backward elimination and included in a multivariate model
adjusted for other signiﬁcant main effects. Using different cut-
points for key covariates in various models (study-speciﬁc or
common quartiles for albumin, creatinine, and lymphocytes; 64
or 100 nmol/mmol Cr for NTX, approximating the upper limit of
normal for premenopausal and postmenopausal women, respec-
tively) facilitated testing the robustness of interactions between
these covariates and treatment effects. Because SREs have been
associated with increased mortality [15], some of the models
were adjusted for SRE incidence as a time-dependent variable.3. Results
3.1. Baseline demographics
Three randomised trials of ZOL (4 or 8/4 mg monthly;
n¼1071) versus placebo (n¼571) [3–5] included 1642 patients
with bone metastases from solid tumours. Baseline characteristics
were similar between treatment groups for the individual trials
(Table 1). Complete baseline assessments including bone marker
levels were available for 1126 patients (ZOL, n¼731; placebo,
n¼395).
3.2. Overall survival
The probability of death was similar between ZOL and placebo
in the intention-to-treat population (RR, 0.939; 95% CI, 0.828 to
1.064; P¼ .323), as it was for the subset with complete baseline
assessments (RR, 0.952; 95% CI, 0.813 to 1.114). Median survival
varied considerably between trials because of the different
natural histories of the underlying malignancies; however, there
was no heterogeneity of ZOL effect by study (Pint¼ .935). BaselineTable 1
Patient demographics and baseline disease characteristics.
NSCLC/OST [5] Prost
ZOL (n¼522) Placebo (n¼250) ZOL (
ECOG PS, n (%)
Fully active (0) 110 (21) 50 (20) 184 (
Some impairment (1–2) 407 (79) 200 (80) 250 (
Prior SRE, n (%) 346 (66) 180 (72) 137 (
Baseline NTX, n (%)b
Z64 nmol/mmol Cr 182 (52) 94 (59) 276 (
Z100 nmol/mmol Cr 95 (27) 49 (31) 188 (
Baseline albumin (g/L)
Median (range) 38 (23–50) 38 (22–48) 41(20
Cr, creatinine; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCL
type I collagen; SRE, skeletal-related event; ZOL, zoledronic acid.
Data from Kohno et al. [3], Saad et al. [4], and Rosen et al. [5].
a All patients received 4 mg zoledronic acid.
b Data from the bone marker subset (total n¼1339 across the three trials).covariates associated with worse OS included cancer duration less
than median, prior SRE, LDHZULN, and low albumin (Table 2).
3.3. Baseline variables inﬂuencing overall survival during zoledronic
acid treatment
Models evaluating possible correlations between all baseline
variables and the potential for OS beneﬁt from ZOL (treatment-
by-covariate interaction) were developed, typically dichotomising
baseline NTX using 64 (postmenopausal ULN) or 100 nmol/mmol
Cr (severely elevated pathologic bone resorption) [17] as the
cutpoint. In the multivariate model (Table 2), baseline covariates
associated with signiﬁcantly different probability of survival
beneﬁts from ZOL treatment included analgesic use (Pint¼ .041),
SRE history (Pint¼ .029), NTX level (Pint¼ .039 and.018 for 64 and
100 nmol/mmol Cr, respectively), and albumin level (Pint¼ .002).
3.4. Inﬂuence of increased bone resorption rate on treatment effect
In models using 100 nmol/mmol creatinine as a cutpoint for
NTX (reﬂective of severe bone disease) [17] and categorising
parameters reﬂective of overall health (e.g., albumin, Cr, lympho-
cytes) using study-speciﬁc percentiles, baseline NTX Z100 nmol/
mmol Cr emerged as a signiﬁcant modiﬁer of the ZOL treatment
effect (consistent with earlier reports in NSCLC) [29]. In this
cohort, ZOL reduced the risk of death by 31% (P¼ .0028) versus
placebo, an effect signiﬁcantly different from that for patients
with baseline NTX o100 nmol/mmol Cr (Pint¼ .0121).
3.5. Additional treatment-effect modiﬁers
To assess additional treatment effect modiﬁers, we analysed
reduced multivariate models that dichotomised NTX using 64-
nmol/mmol Cr as cutpoint and categorised albumin, creatinine,
and lymphocytes using common or study-speciﬁc quartiles.
Models using common quartiles to categorise albumin, creatinine,
and lymphocyte levels showed that cancer duration before study
entry (Pint¼ .0125), and prior history of SREs (Pint¼ .0160) were
associated with the likelihood of a survival beneﬁt from ZOL
(Fig. 1). Treatment with ZOL was associated with a 42% reduction
in the risk of death in patients with a history of prior SREs and
cancer duration shorter than the median (HR¼0.576; 95% CI
0.433–0.767; P¼ .0002). Not surprisingly, these characteristics are
consistent with aggressive, rapidly progressing MBD.
Models using study-speciﬁc quartiles to categorise albumin,
creatinine, and lymphocyte levels showed age (Pint¼ .0459), ECOGate cancer [4] Breast cancer [3]
n¼435) Placebo (n¼208) ZOLa (n¼114) Placebo (n¼113)
42) 93 (45) 76 (67) 74 (65)
58) 115 (55) 38 (33) 39 (35)
32) 78 (38) 39 (34) 47 (42)
67) 135 (67) 62 (56) 59 (54)
45) 94 (47) 41 (27) 33 (30)
–50) 42 (27–50) 43 (26–52) 43 (28–53)
C/OST, non-small cell lung cancer and other solid tumours; NTX, N-telopeptide of
Table 2
Analyses for risk of death in zoledronic acid-treated versus placebo-treated
patients (adjusted for chemotherapy and baseline calcium).
Covariate N RR 95% CI P value Pint
Cancer duration .0706
oMedian 538 0.798 0.637 to 0.998 .048
ZMedian 588 1.067 0.855 to 1.332 .565
Age .9917
oMedian 509 0.960 0.752 to 1.225 .742
ZMedian 617 0.961 0.783 to 1.181 .707
Weight .4383
oMedian 549 0.901 0.727 to 1.118 .346
ZMedian 577 1.021 0.811 to 1.285 .858
BPI composite score .1750
oMedian 542 1.047 0.828 to 1.324 .700
ZMedian 584 0.842 0.681 to 1.040 .111
Analgesic use .0411
None 331 1.310 0.912 to 1.882 .144
Some 795 0.861 0.723 to 1.026 .094
ECOG PS .0806
Fully active 450 1.168 0.875 to 1.560 0.291
Some impairment 676 0.860 0.713 to 1.037 0.114
Prior SRE .0291
No 599 1.137 0.905 to 1.428 .271
Yes 527 0.801 0.644 to 0.994 .044
NTX (nmol/mmol) Cr .0388
oULN 445 1.179 0.894 to 1.555 .243
ZULN 681 0.827 0.683 to 1.002 .052
NTX (nmol/mmol) Cr .0178
o100 703 1.083 0.878 to 1.336 .457
Z100 423 0.738 0.582 to 0.937 .012
BALPa .5977
oULN 381 1.011 0.754 to 1.357 .939
ZULN 745 0.921 0.921 to 1.109 .386
LDH .0644
oULN 862 0.993 0.828 to 1.192 .942
ZULN 264 0.707 0.518 to 0.965 .029
Lymphocytes .5863
rMedian 608 0.912 0.742 to 1.122 .384
4Median 5181 0.997 0.782 to 1.269 .978
Haemoglobin .1817
rMedian 691 1.040 0.855 to 1.264 .697
4Median 435 0.831 0.638 to 1.083 .170
SGOT .4257
oULN 815 0.900 0.747 to 1.086 .273
ZULN 311 1.036 0.775 to 1.386 .810
Albumin (quartile) .0024
o1st quartile 242 0.580 0.425 to 0.791 .001
Z1st but o2nd 269 1.227 0.863 to 1.744 .254
Z2nd but o3rd 257 0.799 0.585 to 1.090 .156
Z3rd quartile 358 1.182 0.873 to 1.600 .280
Cr (quartile) .5868
o1st quartile 251 0.788 0.564 to 1.102 .164
Z1st but o2nd 227 0.929 0.664 to 1.300 .668
Z2nd but o3rd 298 1.075 0.784 to 1.474 .654
Z3rd quartile 350 1.000 0.753 to 1.328 .999
Bold text indicates statistically signiﬁcant correlation.
BALP, bone-speciﬁc alkaline phosphatase; BPI, brief pain inventory; CI, conﬁdence
interval; Cr, creatinine; ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status; LDH, lactate dehydrogenase; NTX, N-telopeptide of type I collagen;
Pint, interactive P value for treatment-by-covariate interaction; RR, relative risk;
SGOT, serum glutamic oxaloacetic transaminase; SRE, skeletal-related event; ULN,
upper limit of normal.
a BALP levels in the Japanese breast cancer trial were dichotomised using
40 U/L (the study-speciﬁc median) as the cutpoint because of the low BALP
distribution among those patients.
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levels (Pint¼ .0154) to be signiﬁcantly associated with the like-
lihood of survival beneﬁt from ZOL (Fig. 2). Results from this
model should be interpreted with caution given the small
numbers of patients in individual subgroups. Nonetheless,
patients with albumin levels within the lowest quartile tended
to derive a survival beneﬁt from ZOL regardless of other factors.
The potential for improved survival with ZOL was also morepronounced in patients with impaired ECOG PS. The likelihood of
OS beneﬁt with ZOL was blunted in patients with normal
lymphocyte levels (i.e., in the 2nd and 3rd quartiles), possibly
because these patients might have tolerated any concomitant
chemotherapy better than patients with lymphopaenia.
3.6. Survival beneﬁt from zoledronic acid treatment is not
dependent on SRE prevention
To control for potential effects of SREs on survival [15], the
observed OS beneﬁt with ZOL treatment was evaluated using
treatment-by-covariate interactions for the pooled patient popu-
lation in models categorising albumin and Cr using study-speciﬁc
quartiles, and adjusting for cumulative SRE incidence in three
different waysas a linear effect, a categoric variable, or a time-
dependent stratiﬁcation factor. All of these models yielded highly
consistent results wherein the OS beneﬁts with ZOL were partially
attenuated but always maintained in patients with high baseline
NTX. In the most robust of these models, the OS beneﬁt with ZOL
in the NTXZ100 nmol/mmol Cr subset remained signiﬁcant after
inclusion of a time-dependent covariate recording the cumulative
number of SREs after randomisation as a categoric variable
(Fig. 3). The effect of ZOL on OS therein was signiﬁcantly different
from that observed in patients with baseline NTX o100-nmol/
mmol Cr, regardless of whether the model was adjusted for time-
dependent SRE incidence (Pint¼ .0159) or not (Pint¼ .0106).4. Discussion
Bisphosphonates reduce skeletal morbidity in patients with
advanced cancers involving bone and have become a recom-
mended component of the multidisciplinary treatment of
MBD [1]. However, bone-health beneﬁts have not generally
translated into signiﬁcantly improved OS in phase III trials
[3–5]. These individual placebo-controlled trials were not pow-
ered to evaluate OS differences and included groups of patients
with low SRE rates (e.g., patients with MBD in the skull) [30] or
aggressive metastases in vital organs that may have contributed
substantially to mortality. A bone-targeted therapy would be less
likely to inﬂuence the clinical course of disease in such patients.
In the overall phase III MBD trial population, there was only a
5% nonsigniﬁcant improvement in OS with ZOL treatment. None-
theless, the results herein suggest a beneﬁcial effect of ZOL on
survival (up to 24 months and in addition to SRE prevention) in
patients with MBD and baseline characteristics associated with
aggressive disease and/or poor prognosis. These characteristics
include parameters associated with aggressive bone disease –
namely, high baseline NTX, prior SREs at baseline – or parameters
indicating a poor overall condition (e.g., low albumin levels and
impaired PS). In particular, the survival beneﬁt in patients with
high NTX was observed in multiple analytic models regardless of
how other covariates were categorised, and is biologically plau-
sible given the antiresorptive ability of bisphosphonates. Cancer-
induced osteolysis is the main therapeutic target for bisphospho-
nates and, consistent with other targeted therapy approaches,
measurement of target activity may help identify patient popula-
tions with the greatest likelihood of beneﬁt from treatment.
Furthermore, the larger survival beneﬁt with ZOL in patients
with NTX4100 nmol/mmol Cr (versus a smaller trend in
patients with NTX464 nmol/mmol Cr) suggests a dose-response
effect.
Interestingly, several of the characteristics associated with
potential OS beneﬁts from ZOL have been also associated with
poor clinical outcomes in earlier studies in patients with
advanced cancers. High baseline NTX is associated with increased
Fig. 1. Multivariate model for treatment-by-covariate effects on overall survival beneﬁts with zoledronic acid (ZOL) in patients with complete baseline prognostic
variables (n¼1126). Model was stratiﬁed by tumour type and adjusted for prior chemotherapy status (yes vs. no) and baseline calcium levels (as a continuous variable);
NTX level was dichotomized using 64 nmol/mmol creatinine as cut-point, baseline albumin, creatinine, and lymphocytes were categorized using common quartiles. ECOG
PS, Eastern Cooperative Oncology Group performance status; Q1–Q4, lowest-highest quartiles; SRE, skeletal-related event; ECOG PS¼0 implies fully active; ECOG PSZ1
implies some impairment.
R.E. Coleman et al. / Journal of Bone Oncology 2 (2013) 70–7674risks of SREs and death [17], and low albumin levels have
emerged as negative prognostic indicators in a variety of
advanced cancers [19–23,31]. Factors such as hypoalbuminaemia
and poor PS might also impact treatment decisions (e.g., by
exacerbating the side effects of chemotherapy or by hindering
access to in-clinic treatment), thereby inﬂuencing clinical out-
comes. The strong associations between such ‘‘poor-prognosis’’
variables and the probability of OS beneﬁts from ZOL suggest that
bone-directed therapy continues to provide beneﬁts even in
patients with the most advanced disease; moreover, such patients
might derive even greater beneﬁts from ZOL.
Consistent with recent results from the MRC Myeloma IX trial
[10], the survival beneﬁts associated with ZOL in the present
analyses appeared independently of SRE prevention. If the
observed improvements in OS with ZOL treatment were comple-
tely attributable to preventing potentially life-limiting SREs [15],
the survival beneﬁts would not be sustained in models including
SRE incidence as a competing time-dependent variable. The
consistent maintenance of the OS beneﬁts of ZOL in models
adjusting for SREs suggests that ZOL, in addition to preventing
treatment interruption and cessation because of SREs and the
associated decreases in PS, may exert anticancer effects in some
patient subsets. Of note, the survival impact is greatest in those
patients with NSCLC and OST, whose survival is typically short
and for whom a delay in anticancer treatment of a few weeks may
have more bearing on subsequent outcome.
This study has some limitations. First, it is a retrospective
evaluation of prospectively collected information, and as such
must be considered exploratory. However, the relationships
between osteolysis rate and other modiﬁers of the effect of ZOL
on survival make clinical and biologic sense. Second, only 69% of
patients had complete baseline assessments; however, a dataset
of 1100 patients with MBD is one of the largest populations ever
evaluated for prognostic factors. Third, survival information is
only available for the duration of the respective periods of
extended follow-up (24 months for CRPC, 21 months for NSCLC
and OST, or 12 months for BC) and as a result only a few breast
cancer events contribute to the ﬁndings. Finally, the effect
of new bone-directed therapies on survival remains a topic for
investigation.Denosumab, an inhibitor of receptor activator of nuclear factor
kappa-B ligand (RANKL), has demonstrated comparable or super-
ior efﬁcacy versus ZOL for reducing SREs in head-to-head clinical
trials in patients with MBD from solid tumours [32–34]. None-
theless, OS was similar between treatment arms [32–34], sug-
gesting that SRE prevention alone may be insufﬁcient to alter
survival. Although correlative analyses are yet to be reported,
these trials prospectively collected bone marker data at baseline
and 13 weeks, and present an opportunity to investigate whether
the correlations between elevated osteolysis levels and survival
beneﬁts with antiresorptives are generally applicable.5. Conclusion
Our ﬁndings may help physicians in selecting high-priority
patients for bisphosphonate treatment. Zoledronic acid is indi-
cated for treating patients with MBD from any malignancy [1,35];
however, many patients do not receive treatment (especially in
NSCLC and CRPC). Although it may not be cost-effective to treat
all, assessing NTX or a similar osteolysis marker could help
identify patients who both have a higher risk of SREs (which
can be reduced with ZOL treatment) and who may also derive a
worthwhile OS beneﬁt from this relatively simple and well-
tolerated intervention. Overall, our models suggest that patients
with poor overall prognosis are more likely to derive OS beneﬁts
from ZOL, indicating that aggressive disease or impaired PS
should not preclude ZOL treatment.Funding
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